Nasopharyngeal Cancer Treatment in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Histologically confirmed NPC (biopsy of primary lesion or involved lymph node with pathology review)

• Any AJCC 8th Edition stage (Stage I through IVB) considered for curative-intent treatment; Stage IVC (distant metastatic) considered for palliative or systemic intent

• ECOG Performance Status 0–2 (adequate functional reserve for chemoradiation or systemic therapy)

• Adequate organ function: creatinine clearance ≥50 mL/min (for cisplatin eligibility), ANC ≥1,500/μL, platelets ≥100,000/μL, AST/ALT ≤2.5× ULN, total bilirubin ≤1.5× ULN

• Patients with locoregional recurrence post-radiation who are candidates for re-irradiation (stereotactic body radiotherapy/SBRT or brachytherapy boost) or salvage endoscopic nasopharyngectomy via robotic or endonasal approach

• Patients seeking a second opinion prior to initiating treatment elsewhere

• REQUIRED DIAGNOSTIC WORKUP PRIOR TO TREATMENT INITIATION:

• MRI of the nasopharynx and skull base with gadolinium contrast (preferred primary imaging modality for T-staging)

• PET-CT (18F-FDG) for nodal and distant metastasis staging

• CT of the chest, abdomen, and pelvis (supplementary to PET-CT)

• Endoscopic nasopharyngoscopy with biopsy (primary tumor tissue for histology, EBV-EBER in-situ hybridization, PD-L1 expression scoring)

• Quantitative plasma EBV DNA (pre-treatment baseline; critical prognostic and monitoring biomarker)

• Audiogram (baseline sensorineural hearing function before cisplatin and temporal lobe irradiation)

• Dental evaluation and oral hygiene optimization (mandatory before head and neck radiation to minimize osteoradionecrosis risk)

• Nasopharyngeal swab or serology for EBV VCA-IgA and EA-IgA (epidemiologic/screening context)

• Complete blood count, comprehensive metabolic panel, thyroid function tests (TSH, free T4), LDH

• Echocardiogram (ECHO) if anthracycline-based regimens or cardiac risk factors present

• RELATIVE CONTRAINDICATIONS / SPECIAL CONSIDERATIONS:

• Prior head and neck irradiation overlapping the nasopharynx (re-irradiation requires specialized dosimetric planning; cumulative spinal cord and brainstem dose constraints are absolute limits)

• Severe renal impairment (creatinine clearance <30 mL/min): cisplatin must be substituted with carboplatin or nedaplatin

• Active uncontrolled autoimmune disease or chronic systemic immunosuppression: contraindication to PD-1/PD-L1 checkpoint inhibitors

• Pregnancy: radiation and platinum chemotherapy are contraindicated; treatment requires multidisciplinary oncofertility counseling

• ECOG Performance Status ≥3: systemic chemotherapy dose reduction or best supportive care may be more appropriate

STANDARD CURATIVE-INTENT CHEMORADIATION (Stage II–IVB): The backbone of NPC treatment is concurrent cisplatin (40 mg/m² weekly or 100 mg/m² every 3 weeks) combined with intensity-modulated radiation therapy (IMRT) delivering 70 Gy in 33–35 fractions to the gross tumor volume (GTV), with sequential dose painting to elective nodal regions at 54–63 Gy. Daily IGRT (cone-beam CT verification) ensures sub-millimeter positioning accuracy critical at the skull base. Volumetric-modulated arc therapy (VMAT) is a widely used IMRT delivery technique that reduces treatment time per fraction while maintaining dosimetric precision. Leading Indian and UAE centers have transitioned entirely to VMAT-based IMRT with integrated PET-CT/MRI simulation co-registration, enabling biological target volume delineation.

INDUCTION CHEMOTHERAPY (Stage III–IVB, High Tumor Burden): For patients with bulky N2–N3 nodal disease or T4 primary tumors, induction chemotherapy prior to CCRT improves overall survival and reduces distant metastasis rates. The current preferred induction regimen is gemcitabine plus cisplatin (GP) for three cycles, as demonstrated in the phase III Sun Yat-sen University trial (2019, NEJM), which showed a 3-year failure-free survival benefit of 85.3% vs. 76.5% over CCRT alone. Docetaxel-cisplatin-fluorouracil (TPF) remains an alternative induction backbone at some centers.

ADJUVANT AND MAINTENANCE THERAPY: Post-CCRT adjuvant capecitabine (metronomic dosing) has demonstrated improved failure-free survival in the CAJOTA trial for high-risk patients. Adjuvant cisplatin-fluorouracil (PF) is used at select centers per NPC-0501 trial data, though toxicity burden is significant. Adjuvant EBV-specific cytotoxic T-lymphocyte (CTL) therapy is available at specialized immunotherapy centers in Singapore and India as part of clinical trial access through GAF Healthcare's oncology network.

IMMUNOTHERAPY FOR RECURRENT/METASTATIC NPC: First-line treatment for recurrent or metastatic EBV-positive NPC now incorporates anti-PD-1 checkpoint inhibitors. Camrelizumab + GP (CAPTAIN-1 trial) and tislelizumab + GP (RATIONALE-309 trial) have both demonstrated statistically significant improvements in progression-free survival versus GP chemotherapy alone. Pembrolizumab (KEYNOTE-122) has demonstrated activity in platinum-pretreated settings. PD-L1 CPS (combined positive score) and tumor mutational burden (TMB) are assessed from biopsy tissue to guide immunotherapy eligibility, though EBV-positive NPC generally responds regardless of PD-L1 expression levels.

SALVAGE SURGERY FOR LOCOREGIONAL RECURRENCE: For isolated locoregional recurrence after definitive radiation, surgical options include endoscopic robotic-assisted nasopharyngectomy (transoral or transnasal approach), which has become technically feasible at high-volume skull base surgery centers in India (Tata Memorial Hospital, AIIMS, Apollo Proton Cancer Centre) and the UAE (Cleveland Clinic Abu Dhabi). The robotic platform (da Vinci Xi) and flexible endoscopic systems (Flex Robotic) enable access to the posterior nasopharynx with negative margins while minimizing damage to adjacent cranial nerves. Neck dissection (selective or modified radical) is performed for persistent or recurrent cervical lymphadenopathy.

PROTON BEAM THERAPY: For reirradiation of recurrent NPC or initial treatment in pediatric patients, proton beam therapy offers superior dose distribution with significantly reduced exit dose to the brainstem, temporal lobes, and cochlea compared to photon IMRT. Apollo Proton Cancer Centre in Chennai (India) houses one of Asia's premier proton therapy facilities, capable of pencil beam scanning (PBS) for NPC treatment. This is a key clinical advantage GAF Healthcare offers for patients who are not candidates for conventional re-irradiation.

BRACHYTHERAPY BOOST: For T1 tumors with complete primary response or as a boost to the nasopharyngeal mucosal scar, intracavitary brachytherapy (HDR-192Ir) delivers a highly localized dose while sparing surrounding structures. This technique is used at specialized centers for dose escalation without increasing normal tissue toxicity.

SUPPORTIVE AND INTEGRATIVE ONCOLOGY: All treatment programs at GAF Healthcare partner hospitals include nutritional support (enteral feeding via nasogastric tube when severe mucositis compromises oral intake), speech and swallowing therapy (critical during and after chemoradiation), acupuncture for xerostomia and radiation-induced nausea (evidence-based per ASCO integrative oncology guidelines), and psycho-oncology services.

PRE-ARRIVAL (2–4 WEEKS BEFORE DEPARTURE):

• GAF Healthcare's clinical team receives patient's existing pathology reports, MRI/PET-CT images, and blood work for remote review by the destination oncology team

• Preliminary treatment plan and cost estimate issued within 48–72 hours

• e-Medical Visa application initiated for India (GAF Healthcare provides invitation letter from treating hospital); UAE visit visa or medical visa coordinated with Dubai Health Authority or Abu Dhabi Department of Health

• Dental clearance completed in home country if possible (fluoride tray fabrication recommended before radiation)

• Audiogram and baseline renal function documented

ARRIVAL AND STAGING WORKUP (DAYS 1–5):

• Airport pickup by GAF Healthcare's dedicated patient coordinator

• Inpatient or outpatient staging workup: MRI skull base with gadolinium, PET-CT, endoscopic nasopharyngoscopy with biopsy (if not yet performed), baseline plasma EBV DNA, complete laboratory panel, ECHO, audiogram, dental review

• Multidisciplinary tumor board (MDT) conference: radiation oncologist, medical oncologist, head and neck surgeon, radiologist, pathologist, nutritionist, and speech therapist convene to finalize staging and treatment plan

• Patient and family counseling session: treatment rationale, expected toxicities, supportive care plan, and timeline

INDUCTION CHEMOTHERAPY (IF INDICATED, WEEKS 2–8):

• Three cycles of gemcitabine-cisplatin (GP) administered at 21-day intervals

• Each cycle: Day 1 and Day 8 gemcitabine IV over 30 minutes; Day 1 cisplatin IV with aggressive pre/post hydration protocol (2–4 hours inpatient stay per infusion day)

• Anti-emetic prophylaxis: aprepitant + ondansetron + dexamethasone (NK1/5-HT3/steroid triple regimen)

• Mid-induction PET-CT and plasma EBV DNA reassessment after Cycle 2

• Weekly monitoring: CBC, renal function, electrolytes, magnesium (cisplatin-related hypomagnesemia managed with IV supplementation)

CONCURRENT CHEMORADIATION (WEEKS 6–13, APPROXIMATELY 7 WEEKS):

• Radiation simulation: CT simulation with thermoplastic immobilization mask, MRI/PET-CT fusion, VMAT-IMRT planning (GTV 70 Gy / CTV2 63 Gy / CTV1 54 Gy in 33 fractions)

• Treatment delivery: Monday through Friday, approximately 15–20 minutes per fraction (VMAT)

• Weekly cisplatin 40 mg/m² IV concurrent with radiation (or 3-weekly 100 mg/m² if tolerated and per center preference)

• Weekly on-treatment assessments: clinical toxicity scoring (CTCAE v5.0), weight, oral intake, CBCT positional verification

• Mucositis management: benzydamine mouthwash, magic mouthwash formulations, mucosal barrier agents, low-level laser therapy (LLLT) for radiation mucositis

• Nutritional: nasogastric tube or PEG feeding initiated if oral intake falls below 60% of caloric needs

• Acute toxicities peak at weeks 4–6 of radiation: Grade 3 mucositis, dysphagia, skin erythema, and fatigue are expected and managed proactively

POST-TREATMENT RECOVERY AND MONITORING (WEEKS 14–20):

• Week 1–2 post-completion: acute toxicity resolution begins; intensive nutritional support and swallowing therapy

• First response assessment: MRI nasopharynx and neck + plasma EBV DNA at 8–12 weeks post-CCRT completion

• PET-CT response assessment at 12–16 weeks (per NCCN and ESMO guidelines, premature imaging risks false-positive residual FDG uptake due to post-radiation inflammation)

• Fit-to-fly clearance typically issued at week 6–8 post-CCRT completion if: (a) no uncontrolled acute toxicities, (b) oral intake adequate without enteral support, (c) no active infection, (d) initial response assessment confirms no rapid progression

• Adjuvant capecitabine (if applicable): initiated after CCRT recovery and may continue for 8 cycles; patient can return home and receive this orally with remote monitoring coordination via GAF Healthcare's telemedicine platform

• Surveillance schedule communicated to home oncologist: plasma EBV DNA every 3 months for 2 years; MRI every 3–6 months for 2 years; TSH every 6 months; audiogram annually; dental review every 6 months